Arvinas (ARVN) vs Crescent Biopharma (CBIO)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 8, 2026.
Summary
Crescent Biopharma (CBIO) has outperformed Arvinas (ARVN) over the past year, gaining 17.1% versus a loss of 19.9%. Over five years, ARVN leads with a -91.2% price change compared with -92.9% for CBIO. Crescent Biopharma is the larger company by market cap ($524.5 million vs $484.6 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | ARVN | CBIO |
|---|---|---|
| Share price | $7.51 | $14.12 |
| Market cap | $484.55M | $524.51M |
| 1-day change | +0.81% | +4.67% |
| YTD return | -37.18% | +19.06% |
| 1-year return | -19.89% | +17.08% |
| 5-year return | -91.18% | -92.87% |
| P/E ratio (TTM) | 28.88 | — |
| EPS (TTM) | $0.26 | $-7.63 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $14.51 | $27.41 |
| 52-week low | $6.97 | $8.72 |
| Distance from 52-week high | -48.24% | -48.49% |
| Analyst consensus | buy | strong_buy |
| Avg. price target upside | +85.49% | +123.09% |
| Average volume | 779.46K | 397.58K |
| Shares outstanding | 64.52M | 37.14M |
| Employees | 246 | 69 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- CBIO has outperformed ARVN by 37.0 percentage points over the past year.
About Arvinas
ARVN stock →Arvinas, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company develops proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body's own natural protein disposal system to degrade and remove disease-causing proteins.
Health Care · Biotechnology: Pharmaceutical Preparations · 246 employees
About Crescent Biopharma
CBIO stock →Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Health Care · Biotechnology: Pharmaceutical Preparations · 69 employees
ARVN vs CBIO FAQ
Which is bigger, Arvinas or Crescent Biopharma?
Crescent Biopharma (CBIO) is larger, with a market capitalization of $524.51M compared with $484.55M for Arvinas (ARVN).
Which stock has performed better over the past year, ARVN or CBIO?
CBIO returned +17.08% over the past 12 months, compared with -19.89% for ARVN (price return, excluding dividends). Past performance does not predict future results.
Are Arvinas and Crescent Biopharma in the same industry?
Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.